Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin in T2DM Uncontrolled on Metformin and Empagliflozin
NCT05504226Phase 3Completed
- Sponsor
- Handok
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of teneligliptin in type 2 diabetes mellitus (T2DM), sponsored by Handok. Started Oct 2022; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05504226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504226.